Cartesian Therapeutics Prepares For Potential Treatment Launch With $124.7 Million In Cash
The company expects its cash to fund operations into 2028, with pivotal myasthenia gravis results expected in early 2027.
Cartesian Therapeutics, which develops cell treatments for autoimmune diseases, is expanding its launch preparations with approximately $124.7 million in cash, cash equivalents and restricted cash at September 30. Results accompanying its Thursday SEC filing said that money should support planned operations into 2028, including completion of its late-stage Descartes-08 trial.
Funding Trials And Launch Preparations
Cartesian has expanded its medical affairs and commercial teams ahead of a potential Descartes-08 launch. The company expects myasthenia gravis trial results in the first quarter of 2027 and plans to submit an FDA approval application in mid-2027.
Carsten Brunn, Cartesian’s president and chief executive officer, said its focus includes “preparing the organization for a commercial launch.”
The cash balance includes an initial $50 million financing tranche from K2 HealthVentures and $22.8 million from shares sold through its market offering program this year, after commissions and expenses. RNAC shares rose about 8% to $7.29 in Friday trading.
Trial Costs Rise, Net Loss Narrows
Research spending climbed to $15.6 million in the third quarter, compared with $13.8 million a year earlier. Higher costs for the myasthenia gravis and myositis trials drove the increase, partly offset by lower spending on early-stage programs.
Administrative expenses reached $9.4 million, versus $7.7 million a year earlier, mainly because of professional fees, consulting and employee costs.
The quarterly net loss narrowed to $11.5 million from $35.9 million; basic losses per common share were $0.38 versus $1.38. That improvement came alongside a $10.7 million gain on the revaluation of contingent payment obligations, compared with a $16.9 million loss a year earlier. Operating losses widened to $25.001 million from $21.066 million.
Descartes-08 Faces Its Pivotal Test
Descartes-08 uses patients’ own cells modified with messenger RNA. Cartesian makes treatments individually at its Frederick, Maryland, facility and sends them to physicians for outpatient infusion. Myasthenia gravis causes muscle weakness; myositis involves muscle inflammation.
The late-stage myasthenia gravis trial compares Descartes-08 with a placebo in approximately 100 patients. Treatment consists of six weekly outpatient infusions without preconditioning chemotherapy. Its main goal measures whether patients achieve at least a three-point improvement in daily functioning at month four.
In September, Cartesian presented retreatment findings for five patients whose symptoms returned after an initial treatment course. Retreatment took place a median of 16.6 months after that course ended. At 12 months after retreatment, average improvement on the daily-functioning scale was 6.6 points, and four of the five maintained a clinically meaningful improvement. The company reported no new safety signals.
Cartesian also expects data from a subset of its mid-stage myositis trial and from its pediatric autoimmune-disease trial in the first half of 2027. The myositis findings will help determine a possible path to a pivotal trial. Enrollment continues in the pediatric study, which includes juvenile dermatomyositis.
A separate partnership with WestGene BioPharma remains in preclinical development. Laboratory testing has produced CAR-T cells using WestGene’s targeted lipid nanoparticles; Cartesian plans clinical development after preclinical testing is complete.
The next major Descartes-08 milestone is the late-stage myasthenia gravis readout expected in the first quarter of 2027, ahead of the planned mid-2027 FDA application.
